Last reviewed · How we verify
GLPG1205 capsules
At a glance
| Generic name | GLPG1205 capsules |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2)
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 (PHASE1)
- This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects (PHASE1)
- A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects (PHASE1)
- Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG1205 capsules CI brief — competitive landscape report
- GLPG1205 capsules updates RSS · CI watch RSS
- Galapagos NV portfolio CI